137 related articles for article (PubMed ID: 38849683)
21. Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001).
Shang X; Zhao G; Liang F; Zhang C; Zhang W; Liu L; Li R; Duan X; Ma Z; Yue J; Chen C; Meng B; Ren X; Jiang H
Ann Transl Med; 2022 Feb; 10(4):229. PubMed ID: 35280363
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma.
Lv H; Tian Y; Li J; Huang C; Sun B; Gai C; Li Z; Tian Z
Front Oncol; 2022; 12():864533. PubMed ID: 35574384
[TBL] [Abstract][Full Text] [Related]
23. Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy.
Blair AB; Rosati LM; Rezaee N; Gemenetzis G; Zheng L; Hruban RH; Cameron JL; Weiss MJ; Wolfgang CL; Herman JM; He J
Surgery; 2018 May; 163(5):1090-1096. PubMed ID: 29395234
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: Results from a retrospective study.
Wang W; Yi Y; Jia Y; Dong X; Zhang J; Song X; Song Y
Thorac Cancer; 2022 Mar; 13(6):824-831. PubMed ID: 35118824
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma.
Wu Z; Zheng Q; Chen H; Xiang J; Hu H; Li H; Pan Y; Peng Y; Yao X; Liu P; Sun Y; Li B; Zhang Y
J Thorac Dis; 2021 Jun; 13(6):3518-3528. PubMed ID: 34277047
[TBL] [Abstract][Full Text] [Related]
26. [Neoadjuvant chemoradiotherapy or chemotherapy for locally advanced esophageal cancer?].
Babic B; Fuchs HF; Bruns CJ
Chirurg; 2020 May; 91(5):379-383. PubMed ID: 32140748
[TBL] [Abstract][Full Text] [Related]
27. [A Case of Locally Advanced Thoracic Esophageal Cancer with Larynx Preservation and Curative Resection via Combined Modality Therapy].
Iwama M; Kimura Y; Shiraishi O; Kato H; Hiraki Y; Tanaka Y; Yasuda A; Shinkai M; Imano M; Imamoto H; Yasuda T
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1720-1722. PubMed ID: 29394754
[TBL] [Abstract][Full Text] [Related]
28. First-line chemotherapy improves the resection rate and long-term survival of locally advanced (T4, any N, M0) squamous cell carcinoma of the thoracic esophagus: final report on 163 consecutive patients with 5-year follow-up.
Ancona E; Ruol A; Castoro C; Chiarion-Sileni V; Merigliano S; Santi S; Bonavina L; Peracchia A
Ann Surg; 1997 Dec; 226(6):714-23; discussion 723-4. PubMed ID: 9409570
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant chemotherapy increases the 5-year overall survival of patients with resectable cervical cancer: A systematic review and meta-analysis.
Xu Y; Zhang M; Zhang J; Ng DM; Chen X; Si Y; Shi Y; Li X; Mao D; Yang L
Taiwan J Obstet Gynecol; 2021 May; 60(3):433-441. PubMed ID: 33966724
[TBL] [Abstract][Full Text] [Related]
30. Predisposing factors for larynx preservation strategies with non-surgical multimodality treatment for locally advanced (T3-4) larynx, hypopharynx and cervical esophageal disease.
Suzuki G; Yamazaki H; Ogo E; Abe T; Eto H; Muraki K; Hattori C; Umeno H; Tanaka N; Tanaka T; Nakamura S; Yoshida K
Anticancer Res; 2014 Sep; 34(9):5205-10. PubMed ID: 25202116
[TBL] [Abstract][Full Text] [Related]
31. The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial.
Wang X; Li S; Sun Y; Li K; Shen X; Xue Y; Liang P; Li G; Chen L; Zhao Q; Li G; Fu W; Liang H; Xin H; Suo J; Fang X; Zheng Z; Xu Z; Chen H; Zhou Y; He Y; Huang H; Zhu L; Yang K; Ji J; Ye Y; Zhang Z; Li F; Wang X; Tian Y; Park S; Chen L
BMC Cancer; 2021 Jan; 21(1):20. PubMed ID: 33402102
[TBL] [Abstract][Full Text] [Related]
32. ASO Author Reflections: Neoadjuvant Chemotherapy versus Definitive Chemoradiation Therapy for Locally Advanced Cervical Esophageal Cancer: A Retrospective Study.
Kubo Y; Kato K; Daiko H
Ann Surg Oncol; 2024 May; ():. PubMed ID: 38802715
[No Abstract] [Full Text] [Related]
33. Induction chemotherapy-based larynx preservation program for locally advanced hypopharyngeal cancer: oncologic and functional outcomes and prognostic factors.
Bozec A; Benezery K; Ettaiche M; Chamorey E; Vandersteen C; Dassonville O; Poissonnet G; Riss JC; Hannoun-Lévi JM; Chand ME; Leysalle A; Saada E; Guigay J; Sudaka A; Demard F; Santini J; Peyrade F
Eur Arch Otorhinolaryngol; 2016 Oct; 273(10):3299-306. PubMed ID: 26858198
[TBL] [Abstract][Full Text] [Related]
34. Safety and Feasibility of Robot-Assisted Minimally Invasive Esophagectomy (RAMIE) with Three-Field Lymphadenectomy and Neoadjuvant Chemoradiotherapy in Patients with Resectable Esophageal Cancer and Cervical Lymph Node Metastasis.
van der Horst S; Weijs TJ; Braunius WW; Mook S; Mohammed NH; Brosens L; van Rossum PSN; Weusten BLAM; Ruurda JP; van Hillegersberg R
Ann Surg Oncol; 2023 May; 30(5):2743-2752. PubMed ID: 36707482
[TBL] [Abstract][Full Text] [Related]
35. Risk factors of early recurrence within 6 months after esophagectomy following neoadjuvant chemotherapy for resectable advanced esophageal squamous cell carcinoma.
Yoshida N; Baba Y; Shigaki H; Harada K; Iwatsuki M; Sakamoto Y; Miyamoto Y; Kurashige J; Kosumi K; Tokunaga R; Watanabe M; Baba H
Int J Clin Oncol; 2016 Dec; 21(6):1071-1078. PubMed ID: 27255393
[TBL] [Abstract][Full Text] [Related]
36. Exclusive neoadjuvant chemotherapy in locally advanced resectable gastric and gastro-esophageal junction adenocarcinoma.
Fernandez E; Cacheux W; Frossard JL; Koessler T; Abou M; Moniez M; Huber O; Puppa G; Roth A
Dig Liver Dis; 2017 May; 49(5):552-556. PubMed ID: 28179095
[TBL] [Abstract][Full Text] [Related]
37. A phase III study on neoadjuvant chemotherapy versus neoadjuvant toripalimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: Henan Cancer Hospital Thoracic Oncology Group 1909 (HCHTOG1909).
Zheng Y; Liu XB; Sun HB; Xu J; Shen S; Ba YF; Yan M; Qin Z; Liu BX; Wang ZF; Liu SL; Zhang RX; Chen PN; Liang GH; Yuan D; Li ZX; Liu Q; Wang HR; Li HM; Lv H; Ma X; Zhu J; Yu YK; Xing WQ;
Ann Transl Med; 2021 Jan; 9(1):73. PubMed ID: 33553366
[TBL] [Abstract][Full Text] [Related]
38. Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.
Kokka F; Bryant A; Brockbank E; Powell M; Oram D
Cochrane Database Syst Rev; 2015 Apr; (4):CD010260. PubMed ID: 25847525
[TBL] [Abstract][Full Text] [Related]
39. How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers.
Jeon SK; Lee JM; Lee ES; Yu MH; Joo I; Yoon JH; Jang JY; Lee KB; Lee SH
Eur Radiol; 2022 Jan; 32(1):56-66. PubMed ID: 34170366
[TBL] [Abstract][Full Text] [Related]
40. Multimodal approach for cervical esophageal carcinoma: role of neoadjuvant chemotherapy.
Suzuki G; Yamazaki H; Ogo E; Abe T; Eto H; Muraki K; Hattori C; Umeno H; Nakashima T; Tanaka T; Nakamura S; Yoshida K
Anticancer Res; 2014 Apr; 34(4):1989-92. PubMed ID: 24692736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
